Copeland Capital Management LLC Sells 12,665 Shares of Zoetis Inc. (NYSE:ZTS)

Copeland Capital Management LLC decreased its position in shares of Zoetis Inc. (NYSE:ZTS - Free Report) by 13.2% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 83,145 shares of the company's stock after selling 12,665 shares during the period. Copeland Capital Management LLC's holdings in Zoetis were worth $13,547,000 at the end of the most recent quarter.

Several other hedge funds also recently modified their holdings of the company. Avantra Family Wealth Inc. bought a new stake in Zoetis during the fourth quarter worth approximately $213,000. DAVENPORT & Co LLC grew its holdings in shares of Zoetis by 11.2% in the 4th quarter. DAVENPORT & Co LLC now owns 62,078 shares of the company's stock worth $10,113,000 after acquiring an additional 6,272 shares during the last quarter. Tokio Marine Asset Management Co. Ltd. raised its position in shares of Zoetis by 55.1% during the fourth quarter. Tokio Marine Asset Management Co. Ltd. now owns 196,127 shares of the company's stock worth $31,955,000 after purchasing an additional 69,658 shares during the period. Capital Insight Partners LLC boosted its position in shares of Zoetis by 9.8% in the 4th quarter. Capital Insight Partners LLC now owns 5,385 shares of the company's stock valued at $877,000 after purchasing an additional 481 shares during the period. Finally, Independence Bank of Kentucky increased its stake in Zoetis by 65.6% in the 4th quarter. Independence Bank of Kentucky now owns 1,043 shares of the company's stock worth $170,000 after purchasing an additional 413 shares in the last quarter. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Zoetis Stock Performance

ZTS traded up $0.30 during trading on Tuesday, reaching $172.24. 2,696,175 shares of the company's stock were exchanged, compared to its average volume of 2,685,644. Zoetis Inc. has a fifty-two week low of $144.80 and a fifty-two week high of $200.53. The company has a market capitalization of $77.71 billion, a P/E ratio of 32.38, a PEG ratio of 2.72 and a beta of 0.90. The company has a quick ratio of 2.27, a current ratio of 3.69 and a debt-to-equity ratio of 1.26. The business has a 50 day moving average price of $169.48 and a 200 day moving average price of $179.39.

Zoetis (NYSE:ZTS - Get Free Report) last posted its quarterly earnings results on Monday, November 4th. The company reported $1.58 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.46 by $0.12. Zoetis had a net margin of 26.55% and a return on equity of 51.98%. The firm had revenue of $2.40 billion during the quarter, compared to analyst estimates of $2.29 billion. During the same quarter in the prior year, the business posted $1.36 earnings per share. The company's quarterly revenue was up 11.6% compared to the same quarter last year. As a group, analysts predict that Zoetis Inc. will post 5.9 earnings per share for the current fiscal year.

Zoetis Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 4th. Shareholders of record on Tuesday, January 21st will be given a dividend of $0.50 per share. The ex-dividend date is Tuesday, January 21st. This is an increase from Zoetis's previous quarterly dividend of $0.43. This represents a $2.00 dividend on an annualized basis and a yield of 1.16%. Zoetis's dividend payout ratio is presently 37.59%.

Analyst Ratings Changes

A number of research analysts recently commented on the stock. Morgan Stanley lowered their price objective on shares of Zoetis from $248.00 to $243.00 and set an "overweight" rating on the stock in a research report on Wednesday, January 29th. JPMorgan Chase & Co. lifted their price target on shares of Zoetis from $225.00 to $230.00 and gave the company an "overweight" rating in a research report on Friday, October 11th. UBS Group started coverage on shares of Zoetis in a research report on Monday, December 9th. They set a "neutral" rating and a $196.00 target price for the company. Stifel Nicolaus decreased their target price on Zoetis from $210.00 to $180.00 and set a "buy" rating for the company in a research note on Tuesday, January 7th. Finally, Leerink Partners initiated coverage on Zoetis in a report on Monday, December 2nd. They issued an "outperform" rating and a $215.00 target price on the stock. One equities research analyst has rated the stock with a hold rating, ten have issued a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, Zoetis presently has an average rating of "Buy" and an average price target of $215.00.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.